2m 2m 2m 2m 2m 2m 2m
- $314.1MMarket Cap
- 5.41%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
ALPHA TEKNOVA (TKNO)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 78
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
Alpha Teknova (TKNO) announced it will report third quarter 2026 financial results on November 4, 2026, followed by a webcast and conference call at 6:00 p.m. ET. The company, a producer of critical reagents for life sciences, also recently announced a $40 million public offering of common stock.
10/21/2026, 6:30 PM • GlobeNewswire
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
Alpha Teknova (TKNO) announced the pricing of an underwritten public offering of 8 million shares at $5.00 per share, generating $40 million in gross proceeds. The offering is expected to close on October 22, 2026. Teknova intends to use net proceeds for general corporate purposes, including potential debt repayment and strategic acquisitions.
10/20/2026, 10:30 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Key Executives
- Stephen Gunstream
- Matthew C. Lowell
- Damon A. Terrill
- Jennifer Henry
Current Ownership Distribution
- Institutions121.8M (72.38%)
- Mutual Funds30.0M (17.82%)
- Insiders16.5M (9.80%)
- Other0 (0.00%)